Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.

Author List
Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Pikman Y, Cheng ML, Logan AC, Stieglitz E, Smith CC
Publication ID (Profile URL)
https://researcherprofiles.org/profile/679825312
Publication Year
2025
PubMed ID
40661530